These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33206598)

  • 1. Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.
    Rizzo A; Mollica V; Massari F
    Eur Urol Oncol; 2020 Dec; 3(6):806. PubMed ID: 33206598
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
    Stopsack KH
    Eur Urol; 2021 Mar; 79(3):e81-e82. PubMed ID: 33358233
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
    Ludmir EB; McCaw ZR; Wei LJ
    Eur Urol; 2021 Jan; 79(1):e10-e11. PubMed ID: 33109378
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
    de Bono J; Hussain M; Kang J
    Eur Urol; 2021 Mar; 79(3):e83-e84. PubMed ID: 33358234
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
    von Eyben FE; Bauman G
    Eur Urol; 2020 Mar; 77(3):e67-e68. PubMed ID: 31300234
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
    Rocco B; Sighinolfi MC
    Eur Urol; 2020 Mar; 77(3):e69. PubMed ID: 31151677
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Qi F; Xu Z; Zou Q
    Eur Urol; 2023 Mar; 83(3):e76-e77. PubMed ID: 36604272
    [No Abstract]   [Full Text] [Related]  

  • 8. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.
    McHenry MB; Drake CG; Fizazi K
    Eur Urol; 2021 Jan; 79(1):e12-e13. PubMed ID: 33121826
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    Loehr A; Chowdhury S; Abida W
    Eur Urol; 2023 Mar; 83(3):e78. PubMed ID: 36623951
    [No Abstract]   [Full Text] [Related]  

  • 11. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Di Lorenzo G; Autorino R
    Eur Urol; 2020 Nov; 78(5):767-768. PubMed ID: 32624284
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Cumberbatch M; Condon B; Lawrentschuk N; Murphy DG
    Eur Urol; 2021 Feb; 79(2):319-320. PubMed ID: 32980168
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.
    Roviello G; Bottini A; Generali D
    Eur Urol; 2016 Aug; 70(2):e41. PubMed ID: 27181830
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in
    Mateo J; de Bono JS; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Agarwal N; Olmos D; Thiery-Vuillemin A; Özgüroğlu M; Mehra N; Matsubara N; Young Joung J; Padua C; Korbenfeld E; Kang J; Marshall H; Lai Z; Barnicle A; Poehlein C; Lukashchuk N; Hussain M
    J Clin Oncol; 2024 Feb; 42(5):571-583. PubMed ID: 37963304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.
    Wallis CJD; Klaassen Z; Jackson WC; Dess RT; Reichert ZR; Sun Y; Spratt DE
    JAMA Netw Open; 2021 May; 4(5):e2110950. PubMed ID: 34028551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.
    Fizazi K; De Porre P; Londhe A; McGowan T; Ryan CJ
    Eur Urol; 2016 Aug; 70(2):e42. PubMed ID: 27209539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.